PhD Candidate: TME Modulation to Boost Radiotherapy

Radboudumc; Nijmegen; On-site; EUR 32,000 - 42,000; Full time

Job summary

Radboudumc in Nijmegen invites applications for a PhD project focused on modulating the tumor microenvironment to enhance radiotherapy responses. The research integrates patient-derived models with in vivo tumor models to dissect how TME features drive resistance and to explore strategies targeting CAFs, hypoxia, senescence, and immune interactions.

The ROI lab combines imaging, molecular, cellular, and immunological approaches to translate mechanistic insights into novel therapies, within an

Qualifications

• An MSc degree in Biomedical Sciences, Biology, Cancer Biology, or a related field, or an equivalent degree.
• A strong interest in preclinical cancer research.
• Motivated to investigate biological mechanisms underlying treatment response.
• Curious, enthusiastic about experimental science, and enjoy working in an interdisciplinary research environment.
• Experience with molecular and cellular biology, tumor biology, radiobiology or immunology is an advantage.
• Experience with preclinical animal models is welcome, and candidates with an Article 9 certificate for working with experimental animals are encouraged to apply.
• This position requires a Certificate of Conduct (VOG).

Responsibilities

• Investigate how modulation of the tumor microenvironment can enhance radiotherapy response.
• Work with patient-derived models and in vivo tumor models to study TME characteristics and treatment resistance.
• Assess readouts such as DNA damage/repair and tumor growth to understand mechanisms.
• Collaborate within the ROI lab to translate mechanistic insights into potential therapeutic strategies.

Skills

Preclinical cancer research

Interdisciplinary collaboration

Motivated to investigate mechanisms

Education

MSc in Biomedical Sciences or related field

Tools

Animal models

Job description

Radboudumc in Nijmegen invites applications for a PhD project focused on modulating the tumor microenvironment to enhance radiotherapy responses. The research integrates patient-derived models with in vivo tumor models to dissect how TME features drive resistance and to explore strategies targeting CAFs, hypoxia, senescence, and immune interactions.

The ROI lab combines imaging, molecular, cellular, and immunological approaches to translate mechanistic insights into novel therapies, within an